Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Adisseo France SAS has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution path. CRUM, MARY ABOU NADER is the busiest examiner, with 1 pending matter attributed to that examiner.
This concentration gives counsel a single examiner record and a single art-unit context to review when preparing the response. The pending matter appears procedurally focused rather than distributed across multiple examination groups. Claim amendments, argument strategy, and interview preparation can therefore be aligned to the identified examiner and the biotechnology and pharmaceutical classification.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRUM, MARY ABOU NADER | 1 | 39.8% | +64.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17746731 | Bacillus strains improving health and performance of production animals | CRUM, MARY ABOU NADER | 40d |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17746731 | Bacillus strains improving health and performance of production animals | CRUM, MARY ABOU NADER | 1657 | §103Other | Final Rejection | 40d | Pending | May 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdisseo France SAS has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Mary Abou Nader Crum has the most, with 1 of Adisseo France SAS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.